This article is more than 5 years old. Information may no longer be current.

Novartis posts double-digit growth in 2004

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BASEL, Switzerland — Novartis reported net sales of $28.25 billion in 2004, an increase of 9% in local currencies from its 2003 sales, according to a financial press release.

Leading the company’s sales in ophthalmology was Visudyne (verteporfin for injection), for the treatment of age-related macular degeneration. Visudyne sales increased 25% in 2004 from 2003 levels, to $448 million for the year, the release said. Specifically, Visudyne posted sales of $209 million in the United States, an increase of 15% from 2003, while rest-of-the-world sales increased 25% to $239 million, the release noted. Novartis attributed part of the increase in U.S. sales to improved Medicare reimbursement for additional lesion types. Novartis comarkets Visudyne with QLT Therapeutics.

CIBA Vision, the contact lens and lens-care division of Novartis, increased full year sales 8%, to $1.41 billion from $1.31 billion in 2003, the release said. CIBA Vision posted U.S. sales of $481 million, an increase of 4% from 2003; outside the United States, CIBA posted sales of $931 million, a 10% increase from 2003.